



April 17, 2019
FunPep Co., Ltd.

Initiation of Phase I/IIa Clinical Trial of Antibody-inducing Peptide FPP003

FunPep Co., Ltd. ("FunPep") is pleased to announce that the first patient has been dosed with antibody-inducing peptide FPP003 in an Australian Phase I/IIa clinical trial.

FunPep has been conducting collaborative research and development of antibody-inducing peptides with institutions such as Osaka University Graduate School of Medicine. Antibody-inducing peptides are peptide drugs designed to cause the body to produce antibodies that inhibit the function of the target molecule. They are characterized by the fact that they maintain antibody levels, which is expected to provide sustained efficacy after administration once every few months. Antibody-inducing peptides also have the potential to be affordable alternatives to traditional antibody drugs, which require heavy investment in biomanufacturing facilities.

FPP003 is an antibody-inducing peptide drug for the treatment of psoriasis. FunPep is continuing research with the goal of providing FPP003 as an alternative therapeutic option to psoriasis patients as a long-acting drug with longer intervals between doses and increased patient convenience.

This Phase I/IIa study is a First-in-Human Study of FPP003 targeting patients with plaque psoriasis. While the primary endpoint is safety, FunPep will also conduct an exploratory evaluation of efficacy.